Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) shot up 4.5% during mid-day trading on Friday . The company traded as high as $7.26 and last traded at $7.24. 24,047 shares traded hands during mid-day trading, a decline of 22% from the average session volume of 30,717 shares. The stock had previously closed at $6.93.
Actuate Therapeutics Stock Performance
The business has a 50 day moving average of $8.34 and a 200-day moving average of $8.17.
Hedge Funds Weigh In On Actuate Therapeutics
Hedge funds have recently modified their holdings of the business. BIOS Capital Management LP acquired a new stake in Actuate Therapeutics during the 4th quarter worth $78,753,000. Voss Capital LP acquired a new stake in shares of Actuate Therapeutics during the fourth quarter worth about $440,000. Northwestern University purchased a new position in shares of Actuate Therapeutics during the third quarter worth about $207,000. Mercer Global Advisors Inc. ADV acquired a new position in Actuate Therapeutics in the 4th quarter valued at about $130,000. Finally, Sigma Planning Corp purchased a new stake in Actuate Therapeutics during the 4th quarter valued at approximately $128,000.
About Actuate Therapeutics
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Read More
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
